Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

149.58 +2.89 (+1.97%)
Official Closing Price Updated: 7:00 PM EDT, Mar 23, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,286,679
Open 149.71
Bid (Size) 149.55 (1)
Ask (Size) 150.15 (3)
Prev. Close 146.69
Today's Range 149.15 - 151.50
52wk Range 95.02 - 157.87
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Chart Of The Day: Novo Nordisk - All Time High
Revenue is expected to grow 17.80% this year and another 13.50% next year. Earnings are estimated to increase by 32.70% this year and an additional 10.90% next year. 
Via Talk Markets
Looking Into Novo Nordisk's Recent Short Interest
 
Via Benzinga

Performance

YTD
+9.21%
+9.21%
1 Month
+4.89%
+4.89%
3 Month
+11.94%
+11.94%
6 Month
+52.15%
+52.15%
1 Year
+36.77%
+36.77%

More News

Read More
2 Top Healthcare Stocks to Buy for the Long Haul
Via The Motley Fool
Three Is Company - Sanofi Follows Lilly, Novo Nordisk, Slashes Insulin Product Price By 78%
Via Benzinga
Novo Nordisk Suspended From UK Trade Association For Practice Breaches
Via Benzinga
Novo Nordisk Follows Eli Lilly In Slashing Insulin Prices By 75%
Via Benzinga
Best-Selling Drugs by Bristol Myers, Pfizer, AbbVie Likely Candidates For US Price Negotiation
Via Benzinga
Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 5 Years
Via Benzinga
If You Invested $100 In This Stock 5 Years Ago, You Would Have $300 Today
Via Benzinga
Jimmy Kimmel Jokes At Oscars About Hollywood Stars Using This Diabetes Drug To Lose Weight — Roasts Will Smith Slap Too
Via Benzinga
BRTX’s ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome
Via TheNewswire.com
BRTX’s ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome
Via News Direct
BRTX's ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome
Via Benzinga
Novo Nordisk: Impulsive Sequence Favors Upside & Remain Supported
Via Talk Markets
Looking To Shed Some Pounds? WeightWatchers To Offer Weight-Loss Drugs Like Ozempic
Via Benzinga
WW Stock Soars As Telehealth Deal Opens Up Hot Obesity Drug Market
Via Investor's Business Daily
AI Stock Headlines 5 Leaders Flashing Buy Signals As Market Rally Gains Steam
Via Investor's Business Daily
Eli Lilly Slashes Insulin Prices By 70%, Will Other Insulin Makers Follow Suit?
Via Benzinga
Analysts Sees Over 50% Upside Opportunity For This Newly Listed Obesity Player Stock, Participating In Big Pharma Race
Via Benzinga
Novo Nordisk: Big Gains In Diabetes And Obesity Care
Via Talk Markets
With COVID-19 Having Placed A Sharp Focus On Syringes, This Innovator Looks Back At A Year Of Successes Since Their 2022 IPO
Via Benzinga
2 Market-Beating Growth Stocks That Are Just Getting Started
Via The Motley Fool
BioRestorative Therapies Inc (NASDAQ: BRTX) Announces European Patentability Of ThermoStem® Program With Indications In Obesity And Type 2 Diabetes
Via TheNewswire.com
Topics Intellectual Property
Exposures Intellectual Property
BioRestorative Therapies Inc (NASDAQ: BRTX) Announces European Patentability Of ThermoStem® Program With Indications In Obesity And Type 2 Diabetes
Via Benzinga
Danaher Shows Interest In Acquiring Catalent Valued At Significant Premium: Report
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.